



47 Year-Old Female with Headache

Olesya Krivospitskaya, MD

Second year endocrinology fellow

HPI:

- 47 y.o. female presented to ER with c/o acute onset of headache at the vertex of her head and retro-orbital pressure started several hrs before her presentation to ER
 - It was 8/10 in intensity
 - Not associated with nausea, vomiting or visual changes
 - She did not have any neurological changes associated with her headache
 - Headache was similar to her „sinus,, headaches, however greater in intensity
-

HPI:

■ **PMH:**

- Morbid obesity
- DM2 diagnosed 1 years ago
- Asthma
- HTN
- HLD
- Plantar fasciitis
- Sinus headaches
- Diabetic neuropathy

■ **FH:**

- Mother and maternal grandmother with DM2

■ **SH:**

- Lives at home with 2 children (13 and 14 years old),
 - unemployed,
 - no smoking, alcohol or illegal drugs
-


Meds:

- Albuterol
 - Amitriptyline
 - Neurontin
 - Lantus 20 units/day
 - Metformin 500mg BID
 - Lisinopril
 - Monteleukast
 - Simvastatin
-

CT head 10/04:



Probable hemorrhagic
pituitary mass

-
- 
- THE UNIVERSITY OF
CHICAGO
MEDICINE
- Endocrinology consulted for the evaluation of pituitary function
-

Review of system:


- Menarche at age 12, G2P2, breastfed her 1 child, but not the second child (did not want too), menstrual cycles stopped 6 months ago, which she attributed to menopause (they were irregular in the last 2 years and she also experienced hot flashes)
 - No hx of galactorrhea
 - No hx of visual problems
 - No hx of changes in her clothes or shoe size in the last few years
 - No hx of easy bruising, stretch marks, acne, muscular weakness
 - No hx of hirsutism

 - Diabetes was diagnosed 1 year ago, when her screening HA1C done by PCP was 13. She was started on Lantus 20 units/day, metformin 500mg BID and life-style modifications. Reported HA1C is 6.7 from 3 months ago. Reports her fasting blood sugars 80-110 and postprandial blood sugars 120-140. Reports hx on numbness in tingling sensation in her hands and feet for about 2-3 years.
-

Physical exam:

- Vitals: BP 150/83, T 37.2C, RR 16, Ht 172.7cm, Wt 169.6kg, BMI 56.87, Sat 97%
- General: not in acute distress
- Eyes: PERLA, no visual defects on confrontation
- Neck: no thyromegaly
- Heart: RRR, no murmurs
- Lungs: CTAB
- Abdomen: BS+, soft, nontender, nondistended
- Skin: **+acanthosis nigricans of the neck. Mild facial hair growth – upper lip, chin.** Ferriman-Gallwey score was 3.
- LE: no peripheral edema
- Neuro: AAOx3, no cranial nerve defect, normal DTR and motor tone

Labs 10/04:



Ca 9 (8.4-10.2 mg/dL)

Total protein 7.7 (6-8.3 g/dL)

Bilirubin, total 0.6 (0.1-1 mg/dL)

Bilirubin, conjugated 0.2 (0-0.3 mg/dL)

Bilirubin, unconjugated 0.5 (0.1-1 mg/dL)

Alk Phos 86 (30-120 U/L)

AST 16 (8-37 U/L)

ALT 19 (8-35 U/L)

HA1C 8.3

PT 12.4 (11.8-14.5 s)

INR 0.9 (0.9-1.1)

PTT 31.6 (24-34 s)

Labs 10/04:

ACTH 21 at 8PM

Cortisol 9.8 at 8PM

LH 12.5

FSH 16.8

Estradiol 20

Prolactin 13.7


IGF1 105

TSH 0.89

Free T4 0.9

-
- The pt was seen by neurosurgery, ophthalmology evaluation and MRI were recommended, however the pt needed to leave AMA due to family reasons
 - Endocrine labs were not available at the time the pt signed up to leave AMA
 - The pt returned to ER for further evaluation in 2 days
-

MRI:



Area of acute hemorrhage measuring 1x1.3x1.2cm not significantly changed from prior CT

-
- The pt was seen by ophthalmology and had no visual field defects
 - Neurosurgery planned to watch her conservatively without a surgical intervention

Labs:

10/04

ACTH 21 at 8PM
Cortisol 9.8 at 8PM
LH 12.5
FSH 16.8
Estradiol 20
Prolactin 13.7
IGF1 105
TSH 0.89
Free T4 0.9

10/07

ACTH 55.9 at 12PM
Cortisol 21.5 at 12PM
TSH 1.04
Free T4 0.88
Total T3 140

10/10

ACTH 53 at 8AM
Cortisol 21.9 at 8AM

-
- The pt was instructed to have her ACTH and cortisol levels checked at 7-8 AM in 3 days
 - She was given a clinic appointment

Labs:

10/04

ACTH 21 at 8PM
Cortisol 9.8 at 8PM
LH 12.5
FSH 16.8
Estradiol 20
Prolactin 13.7
IGF1 105
TSH 0.89
Free T4 0.9

10/07

ACTH 55.9 at 12PM
Cortisol 21.5 at 12PM
TSH 1.04
Free T4 0.88
Total T3 140

10/10


ACTH 53 at 8AM
Cortisol 21.9 at 8AM

-
- 
- THE UNIVERSITY OF
CHICAGO
MEDICINE
- The pt was started on hydrocortisone 10/5 and levothyroxine 50mcg/day
-

Clinical questions:

- What is the mechanism of pituitary apoplexy?
 - Who needs surgical treatment and who should be managed conservatively?
 - Hypopituitarism with pituitary apoplexy
-

Pituitary circulation



Mechanisms of pituitary apoplexy:

- **Theory 1:** growing pituitary tumor compresses pituitary stalk causing interruption of blood supply, ischemia and necrosis of both pituitary tumor and anterior pituitary
 - **Theory 2:** critical perfusion pressure of pituitary adenomas is below normal arterial pressure and that sudden alterations in perfusion pressure predispose the adenoma to infarction
 - **Theory 3:** as the tumor enlarges, it outgrows its blood supply resulting in ischemic necrosis and secondary hemorrhage
-

Presenting symptoms of pituitary apoplexy

Table 3. Presenting Signs and Symptoms of Pituitary Tumor Apoplexy Extracted From Recently Reported Series Involving More than 400 Patients

| Sign or Symptom | % of Patients | | |
|---|---------------|------|--------|
| | Range | Mean | Median |
| Headache | 63-100 | 93 | 96 |
| Visual symptoms | | | |
| Nerve palsies | 40-100 | 68 | 69 |
| Decreased visual acuity or visual field defects | 40-100 | 75 | 73 |
| Lethargy, altered consciousness meningismus | 0-42 | 22 | 24 |
| Nausea or vomiting, other nonspecific symptoms | 20-77 | 37 | 42 |

Surgical vs conservative approach

| | Conservative management (<i>n</i> = 20) | Surgical management (<i>n</i> = 10) | Overall (<i>n</i> = 30) |
|----------------------------------|---|---|-----------------------------|
| Age | 23–86 (54) | 17–70 (46.5) | 17–86 (53.5) |
| Gender | | | |
| Male | 16 (80%) | 7 (70%) | 23 (77%) |
| Female | 4 (20%) | 3 (30%) | 7 (23%) |
| Headache | 17 (85%) | 10 (100%) | 27 (90%) |
| Decreased conscious level | 3 (15%) | 0 | 3 (10%) |
| Vomiting | 8 (40%) | 6 (60%) | 14 (47%) |
| Blind | | | |
| One eye | 1 (5%) | 1 (10%) | 2 (7%) |
| Both eyes | 3 (15%) | 1 (10%) | 4 (13%) |
| No visual deficit | 4 (20%) | 1 (10%) | 5 (17%) |
| Blind excluded (<i>n</i> = 24): | | | |
| Reduced visual acuity (VA) | 7 (44%) | 5 (62.5%) | 12 (50%) |
| Acuity worse than 6/18 | 3 (19%) | 3 (37.5%) | 6 (25%) |
| Reduced visual field (VF) | 4 (25%) | 6 (75%) | 10 (42%) |
| > 50% field loss | 1 (6%) | 4 (50%) | 5 (21%) |
| Ophthalmoplegia | 12 (75%) | 3 (37.5%) | 15 (62.5%) |

TABLE III. Outcome of visual defects in patients treated conservatively compared with patients treated surgically. Some patients had more than one of loss of visual acuity, loss of fields and/or ophthalmoplegia

| Feature and outcome | Conservative management | Surgical management |
|---|-------------------------|---------------------|
| Any visual defect | | |
| Complete resolution | 8 (40%) | 2 (20%) |
| Partial resolution | 6 (30%) | 5 (50%) |
| No change (No defect) | 2 (10%) | 2 (20%) |
| No change (No defect) | 4 (20%) | 1 (10%) |
| Blindness (<i>n</i> = 6) (mono- or binocular) | | |
| Partial resolution | 2 (50%) | 1 (50%) |
| No change | 2 | 1 |
| Loss of acuity (excluding blindness, <i>n</i> = 24) | | |
| Complete resolution | 5 (71%) | 4 (80%) |
| Partial resolution | 2 (29%) | 1 (20%) |
| No change (No defect) | 0 | 0 |
| No change (No defect) | 9 | 3 |
| Loss of field (excluding blindness) | | |
| Complete resolution | 2 (50%) | 2 (33%) |
| Partial resolution | 1 (25%) | 3 (50%) |
| No change (No defect) | 1 (25%) | 1 (17%) |
| No change (No defect) | 12 | 2 |
| Ophthalmoplegia (excluding blindness) | | |
| Complete resolution | 10 (83%) | 2 (67%) |
| Partial resolution | 2 (17%) | 1 (33%) |
| No change (No defect) | 0 | 0 |
| No change (No defect) | 4 | 5 |

Panhypopituitarism post apoplexy

Table 4. Impairment in Pituitary Function in Patients With Pituitary Tumor Apoplexy at Presentation Extracted from Published Series


| % of patients with deficiency | Pituitary Axis Involved | | | |
|-------------------------------|-------------------------|-----------|---------|------------------------|
| | Adrenal | Thyroidal | Gonadal | Prolactin ^a |
| Range | 50-100 | 25-75 | 60-100 | 6-40 |
| Mean | 67 | 45 | 82 | 23 |

^aFrequently not determined.

- Since the pts has macroadenomas, the majority of them has at least partial hypopituitarism before apoplectic episode
- 50% of the pts are able to at least partially recover pituitary function
- However about 80% of pts need at least one form of hormone replacement
- Levels of prolactin at presentation could have a prognostic function: normal or high prolactin levels at presentation tend to have better pituitary function

Proposed algorithm of pituitary apoplexy management

Urgent biochemical/and endocrine evaluation
(Haemogram, electrolytes, LFT, KFT, clotting profile,
Serum cortisol, T₄, TSH, PRL, GH, IGF-I, LH, FSH, testosterone or estradiol)



Take home points:

- Pituitary apoplexy is a potentially life-threatening disorder, requiring urgent evaluation of pituitary function and hormone replacement as necessary
 - Cases with no visual deficits, optic chiasm compression, or neurological deficits could potentially be managed conservatively
 - Pituitary function should be reevaluated in 4-6 weeks after the episode apoplexy and then annually based on expert opinion
-

References:

- Pituitary apoplexy: evaluation, management, and prognosis. Murad-Kejbou S, Eggenberger E. *Curr Opin Ophthalmol*. 2009 Nov;20(6):456-61.
 - Pituitary tumor apoplexy: a review. Nawar RN, AbdelMannan D, Selman WR, Arafah BM. *J Intensive Care Med*. 2008 Mar-Apr;23(2):75-90.
 - Pituitary apoplexy: retrospective review of 30 patients--is surgical intervention always necessary? Gruber A, Clayton J, Kumar S, Robertson I, Howlett TA, Mansell P. *Br J Neurosurg*. 2006 Dec;20(6):379-85.
 - Pituitary apoplexy. Ranabir S, Baruah MP. *Indian J Endocrinol Metab*. 2011 Sep;15 Suppl 3:S188-96.
-